ClinVar Miner

Submissions for variant NM_000314.8(PTEN):c.475A>G (p.Arg159Gly)

dbSNP: rs786202688
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000165624 SCV000216360 likely pathogenic Hereditary cancer-predisposing syndrome 2024-02-05 criteria provided, single submitter clinical testing The p.R159G variant (also known as c.475A>G), located in coding exon 5 of the PTEN gene, results from an A to G substitution at nucleotide position 475. The arginine at codon 159 is replaced by glycine, an amino acid with dissimilar properties. This alteration has been reported in individuals with features of Cowden syndrome (Tan MH et al. Am J Hum Genet, 2011 Jan;88:42-56; Busch RM et al. Transl Psychiatry, 2019 Oct;9:253). Yeast studies have indicated that this alteration compromises PTEN protein function (Andrés-Pons A, Cancer Res. 2007 Oct; 67(20):9731-9). In a massively parallel functional assay using a humanized yeast model, lipid phosphatase activity for this variant was functionally deficient (Mighell TL et al. Am J Hum Genet, 2018 May;102:943-955). However, this variant demonstrated wild type-like intracellular protein abundance in a massively parallel functional assay (Matreyek KA et al. Nat Genet, 2018 Jun;50:874-882). Based on the crystal structure for the PTEN protein, Arg159 stabilizes the conformation of the catalytic p-loop and the glycine substitution is expected to disrupt this interaction (Lee JO, Cell 1999 Oct; 99(3):323-34; Rodríguez-Escudero I, Hum. Mol. Genet. 2011 Nov; 20(21):4132-42). This missense alteration is located in a region that has a low rate of benign missense variation (Lek M et al. Nature. 2016 Aug 18;536(7616):285-91; DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Firth H.V. et al. 2009. Am.J.Hum.Genet. 84, 524-533 (DOI: This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000760049 SCV000889803 likely pathogenic not provided 2017-11-03 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001193513 SCV001362399 likely pathogenic Cowden syndrome 2019-12-05 criteria provided, single submitter clinical testing Variant summary: PTEN c.475A>G (p.Arg159Gly) results in a non-conservative amino acid change located in the phosphatase domain (IPR029023) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 250998 control chromosomes (gnomAD). c.475A>G has been reported in the literature in at least one individual affected with Cowden Syndrome (CS) or CS-like phenotype (Tan_2011). These data do not allow clear conclusions about variant significance. One publication reported experimental evidence and demonstrated that the variant protein expressed in mammalian cells resulted in increased levels of Akt1 phosphorylation (Andres-Pons_2007). In addition, another variant affecting the same amino acid (R159T) was reported to be found in a patient affected with CS or CS-like phenotype (HGMD, Tan_2011), further supporting a functional role for the affected residue. One ClinVar submitter (evaluation after 2014) cited the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Invitae RCV002515152 SCV003439628 pathogenic PTEN hamartoma tumor syndrome 2022-02-11 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects PTEN function (PMID: 17942903). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). ClinVar contains an entry for this variant (Variation ID: 186094). This missense change has been observed in individual(s) with clinical features of Cowden syndrome (PMID: 21194675, 31594918; Invitae). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 159 of the PTEN protein (p.Arg159Gly).
GeneDx RCV000760049 SCV003837300 likely pathogenic not provided 2022-09-02 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24475377, 21194675, 29785012, 10555148, 21828076, 17942903, 31594918, 29706350)

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.